Wenjun Wu

1.4k total citations
69 papers, 830 citations indexed

About

Wenjun Wu is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Wenjun Wu has authored 69 papers receiving a total of 830 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 29 papers in Hematology and 25 papers in Molecular Biology. Recurrent topics in Wenjun Wu's work include CAR-T cell therapy research (23 papers), Multiple Myeloma Research and Treatments (21 papers) and Virus-based gene therapy research (10 papers). Wenjun Wu is often cited by papers focused on CAR-T cell therapy research (23 papers), Multiple Myeloma Research and Treatments (21 papers) and Virus-based gene therapy research (10 papers). Wenjun Wu collaborates with scholars based in China, United States and Israel. Wenjun Wu's co-authors include He Huang, Guoqing Wei, Jingsong He, Yongxian Hu, Zhen Cai, Xiaoyan Han, Gaofeng Zheng, Alex H. Chang, Yanlei Zhang and Jimin Shi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Wenjun Wu

62 papers receiving 816 citations

Peers

Wenjun Wu
Chao Xiao China
Xiao-Li Zheng China
Dongjun Lin China
M. Yamashita Japan
Fang Zheng China
Jianbo He China
Jiali Wei China
Zhifen Han China
Chao Xiao China
Wenjun Wu
Citations per year, relative to Wenjun Wu Wenjun Wu (= 1×) peers Chao Xiao

Countries citing papers authored by Wenjun Wu

Since Specialization
Citations

This map shows the geographic impact of Wenjun Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenjun Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenjun Wu more than expected).

Fields of papers citing papers by Wenjun Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wenjun Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenjun Wu. The network helps show where Wenjun Wu may publish in the future.

Co-authorship network of co-authors of Wenjun Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Wenjun Wu. A scholar is included among the top collaborators of Wenjun Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wenjun Wu. Wenjun Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Wenjun, et al.. (2025). Thermal–nanoconfinement synergistic catalysis driven by low-grade heat for ultrafast and energy-efficient organophosphorus degradation. Applied Catalysis B: Environmental. 380. 125784–125784. 1 indexed citations
2.
3.
4.
5.
Wang, Chenyun, Yang Yang, Donghua He, et al.. (2024). Survival of Hemodialysis-Dependent Multiple Myeloma Patients and Factors Associated with Dialysis Independence: A Real-World Study in China. Blood. 144(Supplement 1). 6913–6913. 1 indexed citations
6.
Zheng, Gaofeng, et al.. (2023). Follicular helper T cells: emerging roles in lymphomagenesis. Journal of Leukocyte Biology. 116(1). 54–63. 1 indexed citations
7.
Shi, Jimin, Xiaoyu Lai, Yanmin Zhao, et al.. (2023). Survival and late mortality among patients who survived disease‐free for 2 years after stem cell transplantation. British Journal of Haematology. 202(3). 608–622. 3 indexed citations
8.
He, Jingsong, Wenjun Wu, Xiaoyan Han, et al.. (2023). Outcomes of COVID‐19 in multiple myeloma patients treated with daratumumab. Cancer Science. 115(1). 237–246. 7 indexed citations
9.
Wang, Yi, Yuxi Zhang, Jilan Chen, et al.. (2023). Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer. International Immunopharmacology. 123. 110686–110686. 7 indexed citations
10.
Wei, Guoqing, Yanlei Zhang, Houli Zhao, et al.. (2021). CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. Cancer Immunology Research. 9(9). 1061–1070. 47 indexed citations
11.
Liang, Bin, Yan Liu, Guoqing Wei, et al.. (2021). Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia. Frontiers in Pharmacology. 12. 702152–702152. 3 indexed citations
12.
He, Donghua, Gaofeng Zheng, Jingsong He, et al.. (2021). The Clinical Characteristics and Prognosis of Chinese Patients with Light-Chain Amyloidosis: A Retrospective Multicenter Analysis. Indian Journal of Hematology and Blood Transfusion. 38(3). 444–453. 3 indexed citations
13.
Jin, Aiyun, Jingjing Feng, Guoqing Wei, et al.. (2020). CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations. Bone Marrow Transplantation. 55(4). 717–721. 7 indexed citations
14.
He, Jingsong, Donghua He, Xiaoyan Han, et al.. (2020). Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data. Frontiers in Pharmacology. 11. 561601–561601. 10 indexed citations
15.
Yang, Yang, Gang Wang, Wenjun Wu, et al.. (2018). Camalexin Induces Apoptosis via the ROS‐ER Stress‐Mitochondrial Apoptosis Pathway in AML Cells. Oxidative Medicine and Cellular Longevity. 2018(1). 7426950–7426950. 30 indexed citations
16.
Zhao, Yi, Enfan Zhang, Ning Lv, et al.. (2018). Metformin and FTY720 Synergistically Induce Apoptosis in Multiple Myeloma Cells. Cellular Physiology and Biochemistry. 48(2). 785–800. 22 indexed citations
17.
Hu, Yongxian, Jiasheng Wang, Chengfei Pu, et al.. (2018). Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy. Cancer Research and Treatment. 50(4). 1462–1466. 10 indexed citations
18.
Wei, Guoqing, Yongxian Hu, Chengfei Pu, et al.. (2018). CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study. Annals of Hematology. 97(5). 781–789. 21 indexed citations
19.
Wei, Guoqing, Lijun Wang, Hanjin Yang, et al.. (2017). Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma. Experimental Hematology and Oncology. 6(1). 16–16. 4 indexed citations
20.
He, Donghua, Xing Guo, Enfan Zhang, et al.. (2016). Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft models. Oncotarget. 7(29). 45489–45499. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chao Xiao Breakdown of academic impact, for papers by Xiao-Li Zheng Breakdown of academic impact, for papers by Dongjun Lin Breakdown of academic impact, for papers by M. Yamashita Breakdown of academic impact, for papers by Fang Zheng Breakdown of academic impact, for papers by Jianbo He Breakdown of academic impact, for papers by Jiali Wei Breakdown of academic impact, for papers by Zhifen Han
Rankless by CCL
2026